

Regd. Office :
1506, Chiranjiv Tower,
43, Nehru Place, New Delhi-110019
CIN No. : L74899DL1993PLC056594

Tel. : 011 - 47589500, 41608929
Tel. : 011 - 21800032
Fax : 011 - 26213081
Web : www.medicamen.com

Ref: STEX/Results/Published-2019-20

Date: 16th August, 2019

The BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Company Number: 531146

**Sub. : Copy of Publication of Un-audited Financial Results for the first Quarter ended on
30th June, 2019**

Dear Sir,

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the copies of newspaper publication pertaining to the Un-audited Financial Results for the first Quarter ended on 30th June, 2019, published in Financial Express (English) and Jansatta (Hindi) newspaper on 15.08.2019.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking You,

Yours truly,
For Medicamen Biotech Limited



Parul Choudhary
Company Secretary

Encl: As above.

ins. The bank had a remarkable increase in sanctioning the number of cases sanctioned shows increase since its...
 ing the limit to ₹5...
 Regd. Office: Ghaziabad
 Email: kaushik...
EXTRA...
 here will be sub...
 ase in the MSME

and also would benefit the borrowers," IOB said in a statement.
 In due course of time, the bank will also offer retail products (housing and personal loans) under this platform, anticipating demand from the borrowers, as the bank reduced its MCLR by 10 to 15 basis points (bps) for different tenors, effective August 10,

the RBI. The 59-minute loan scheme was launched last year for the benefit of MSMEs. It is an integral part of the 12-point action plan for MSMEs which was announced in November 2018.
 To further improve its rate of transmission, the bank is in the process of linking retail loan products with external benchmark repo rate.

crore in April-July 2019, against ₹17,369.32 crore in previous financial year a growth of 26.89%. While first year premiums for LIC stood at ₹60,106.66

Sl. No.	Particulars
1.	Total Income from...
2.	Total Income from...
3.	EBDITA
4.	Net Profit/(Loss) for extraordinary items
5.	Net Profit/(Loss) for extraordinary items
6.	Tax Expense
7.	Net Profit/(Loss) for extraordinary items
8.	Total Comprehensive after tax and other
9.	Paid-up Equity Share
10.	Reserves (excluding)
11.	Earning Per Share - Basic - Diluted

Notes:
 1. The above is an extract of the financial statements of the Company as per the provisions of the Companies Act, 2013 and the Companies (Accounts) Rules, 2014.
 2. The above results were audited by the Statutory Auditors, M/s. Ghaziabad on 14th August 2019.
 3. These results have been approved by the Board of Directors of the Company on 13th August 2019.
 4. As per Ind AS - 108, the modified retrospective impact on the profit of...
 5. Net Profit includes...
 6. Effective from 01 April 2019, the maturity period is extended...

15 years in which at least...
 er details, are...
 bureau.org.in

Secretary Board Bureau...
 n, if any, will be

New Link Road, Ghaziabad, U.P.
 www.hsindia.in
 Date: 14th Aug, 2019

MEETING, INFORMATION
 General Meeting September, 2019
 Colony, J. P. Road, Ghaziabad
 Contact the Business

BLACK R
 Regd. Off.: 145-A
 Tel : +91 22 4333
 Website: www.blackrock.com

STATEMENT OF...
 The same is also

the provisions of Rules thereon and...
 Members and the...
 read with Rule 20...
 Rules, 2014 and...
 and Disclosure

Sl. No.	Particulars
1.	Revenue from operations
2.	Net Profit/(Loss) before Tax
3.	Net Profit/(Loss) after Extraordinary items
4.	Net Profit/(Loss) after Extraordinary items



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi - 110019
 (CIN: L74899DL1993PLC056594) Website: www.medicamen.com
 Email id: cs@medicamen.com

Extracts of Un-Audited standalone Financial Results for the Quarter ended on 30.06.2019

Sl. No.	Particulars	Quarter Ended			
		Quarter Ended		Year Ended	
		Unaudited 30.06.2019	Audited 31.03.2019	Unaudited 30.06.2018	Audited 31.03.2019
1	Total income from operations (net)	3,116.75	3,388.96	3,392.63	12,626.32
2	Net Profit/(Loss) for the period (before tax, exceptional and/ or Extraordinary items)	431.77	421.72	453.99	1,771.19
3	Net Profit/(Loss) for the period before tax (after exceptional and/ or Extraordinary items)	431.77	421.72	453.99	1,771.19
4	Net Profit/(Loss) for the period after tax (after exceptional and/ or Extraordinary items)	328.13	283.94	322.20	1,221.49
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	328.13	283.94	322.20	1,221.49
6	Equity, Share Capital	1,221.66	1,170.00	1,170.00	1,170.00
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)				7,493.36
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)				
	Basic:	2.75	2.43	2.75	10.44
	Diluted:	2.75	2.43	2.75	10.44

Note:

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 14th August, 2019.
- The figures are regrouped in previous year also, wherever considered necessary.
- The Company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Paid-up Share Capital of the Company has been increased from Rs. 11,70,00,000/- to Rs. 12,21,66,000/- pursuant to allotment of 5,16,600 number of Equity Shares @ Rs. 10/- each on dated 21.05.2019
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33- "Earning Per Share"
- Limited Review Report has been carried out by the Statutory Auditors for the above period.

Place: New Delhi
 Date: 14.08.2019

For Medicamen Biotech Limited
 Sd/-
 Rahul Bishnoi
 Chairman

INDIA FINSEC LIMITED

Regd. Office: 16, 1st Floor, Above ICICI Bank, Prashant Vihar, Sector-14, Rohini, New Delhi-110085
 CIN: L65923DL1994PLC060827, Ph: -011-47096097
 E-mail ID: indiafinsec@gmail.com, Website: www.indiafinsec.com

EXTRACT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2019 (IND-AS COMPLIANT)

Sl. No.	Particulars	STANDALONE				CONSOLIDATED	
		Quarter Ended		Previous Year ended	Quarter Ended	Previous Year ended	
		30-Jun-19 (Unaudited)	31-Mar-19 (Unaudited)	30-Jun-18 (Unaudited)	31-Mar-19 Audited	30-Jun-19 (Unaudited)	31-Mar-19 Audited
1	Total income from operations (net)	93.27	52.83	94.68	368.24	385.35	1,086.65
2	Net Profit / (Loss) from ordinary activities before tax	(13.45)	(58.16)	139.15	63.17	63.44	292.29
3	Net Profit / (Loss) for the period after tax (after Extraordinary items)	(9.70)	(59.46)	129.67	63.17	63.44	292.29

Sl. No.	Particulars
1	Total income from operations
2	Net Profit / (Loss) after Extraordinary items
3	Net Profit / (Loss) after Extraordinary items
4	Net Profit / (Loss) after Extraordinary items
5	Total Comprehensive Income
6	Paid up Equity Share Capital
7	Reserves (excluding Revaluation Reserve)
8	Earnings Per Share (Basic / Diluted)

Notes:-
 1 The above unaudited results have been reviewed by the Board of Directors of the Company.
 2 The above is an extract of the financial statements of the Company in the format of the Quarterly Financial Results as prescribed in the Companies Act, 2013 and the Companies (Accounts) Rules, 2014. The same is also available on the website of the Company.

Place : Vadodara
 Date : 14th August, 2019

CY

Registered Corporation

Unaudited

Sl. No.	Particulars
1	Total income from operations
2	Net profit / (loss) after Extraordinary items
3	Net profit / (loss) after Extraordinary items
4	Net profit / (loss) after Extraordinary items
5	Total comprehensive income
6	Paid-up equity share capital
7	Other Equity
8	Earnings per share (Face value per share)
	a) Basic (Rs. per share)
	b) Diluted (Rs. per share)

वेस्ट इंडीज दौरे पर बरकरार रहेंगे सुब्रह्मण्यम

नई दिल्ली, 14 अगस्त (भाषा)।

बीसीसीआइ ने भारतीय टीम के प्रशासनिक प्रबंधक सुनील सुब्रह्मण्यम को कैरेबियाई सर्जमी में भारतीय उच्चायोग के वरिष्ठ

अधिकारियों से कथित दुर्व्यवहार के कारण वेस्ट इंडीज दौरे के बीच से वापस बुलाने का फैसला उनके बिना शर्त माफी मांगने के बाद वापस ले लिया। बीसीसीआइ ने मैनेजर को दौरे के बीच से वापस बुलाने का मन बना लिया था लेकिन प्रशासकों की समिति के प्रमुख विनोद राय ने उनके माफी मांगने के बाद उन्हें कड़ी फटकार लगाकर छोड़ दिया। राय ने कहा कि सुनील सुब्रह्मण्यम

को नहीं र शुरू में शर्त माफी ही रखने कर ली एक शीर्षक जौहरी के



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi - 110019
(CIN: L74899DL1993PLC056594) Website: www.medicamen.com
Email id: cs@medicamen.com

Extracts of Un-Audited standalone Financial Results for the Quarter ended on 30.06.2019

(In Lakhs)

Sl. No.	Particulars	Quarter Ended		Year Ended	
		Unaudited 30.06.2019	Audited 31.03.2019	Unaudited 30.06.2018	Audited 31.03.2019
1	Total income from operations (net)	3,116.75	3,388.96	3,392.63	12,626.32
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	431.77	421.72	453.99	1,771.19
3	Net Profit/ (Loss) for the period before tax (after exceptional and/ or Extraordinary items)	431.77	421.72	453.99	1,771.19
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	328.13	283.94	322.20	1,221.49
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	328.13	283.94	322.20	1,221.49
6	Equity Share Capital	1,221.66	1,170.00	1,170.00	1,170.00
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)				7,493.36
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)				
	Basic:	2.75	2.43	2.75	10.44
	Diluted:	2.75	2.43	2.75	10.44

Note:

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 14th August, 2019.
- The figures are regrouped in previous year also, wherever considered necessary.
- The Company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Paid-up Share Capital of the Company has been increased from Rs. 11,70,00,000/- to Rs. 12,21,66,000/- pursuant to allotment of 5,16,600 number of Equity Shares @ Rs. 10/- each on dated 21.05.2019
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33- "Earning Per Share"
- Limited Review Report has been carried out by the Statutory Auditors for the above period.

For Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Chairman

Place: New Delhi
Date : 14.08.2019

Jaykay Enterprises Limited

CIN: L99999UF1961PLC001187
Regd. Office: Kamla Tower, Kanpur 208 001 (India)
Ph. No.: +91 512 2371478- 8; Fax : +91 512 2332665
website www.jaykayenterprises.com Email: prabhat.mishra@kccement.com

Extract of Statement of Standalone Un-audited Financial Results for the Quarter ended 30th JUNE, 2019 (₹ in lacs)

Sl. No.	Particulars	3 Months Ended	Year Ended	3 Months Ended
		30.06.2019	31.03.2019	30.06.2018
		Un-audited	Audited	Un-audited
1.	Total Income From Operations	7.50	30.60	7.50
2.	Net Profit/(Loss) for the period (before Tax, Exceptional and Extraordinary items.)	10.73	91.03	27.77
3.	Net Profit/(Loss) for the period before tax (after Exceptional and Extraordinary items.)	10.73	91.03	27.77
4.	Net Profit/(Loss) for the period after tax	10.73	69.35	27.77



विनायक पोलीकॉन

पंजीकृत कार्यालय : 312, नवजीवन कॉम्प्लेक्स, 29, फैसल
फैसल : 0141-2378830, ई-मेल : investor@vinaayak.com
CIN : L252

30 जून, 2019 को समाप्त तिमाही के लिए स्टैण्डप

क्रम सं.	विवरण	समाप्त 30.06.2019
1.	परिचालन से कुल आय (शुद्ध)	442
2.	कर के पहले की अवधि के लिए असाधारण और असाधारण वस्तुओं से शुद्ध लाभ/ (हानि)	3.2
3.	कर के पहले शुद्ध लाभ/ (हानि) (असाधारण और/ या असाधारण वस्तुओं से बाद)	3.2
4.	कर के बाद शुद्ध लाभ/ (हानि) (असाधारण और/ या असाधारण वस्तुओं से बाद)	2.3
5.	अवधि के लिए कुल व्यापक आय एवं अन्य व्यापक आय (कर के बाद) के लिए लाभ/ हानि	2.3
6.	समतता अंश पूंजी	308
7.	रिज़र्व (पूर्व लेखा वर्ष के तुलन पत्र के अनुसार पुनर्मूल्यांकन रिज़र्व के अतिरिक्त)	-
8.	आय प्रति शेयर (रु. 10/- प्रति का) (संचालन जारी रखने और बंद करने के लिए)	
	1. मूल	0.0
	2. तरल	0.0

टिप्पणी : (1) इन स्टैंडअलोन वित्तीय परिणाम कंपनी अधिनियम, 2013 की धारा 173(1) के तहत और माप सिद्धान्तों के अनुसार तैयार किये गये हैं, इसके तहत जारी अपेक्षा) विनियमन 33 के अंतर्गत स्टैंडक एक्सचेंज के पास दाखिल किए गए हैं। 30 जून, 2019 को समाप्त तिमाही के वित्तीय परिणामों का संपूर्ण प्रारूप व विवरण (www.vinayakpolycon.com) पर उपलब्ध है।

स्थान: जयपुर
दिनांक: 14 अगस्त, 2019

TEMPLE LEASING AN

Office: 116A, 1st Floor, Somdutt Chamber-
Email: Email: temple3884@gmail.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS

S. NO.	PARTICULARS	QUARTER ENDED
		30.06.2019
		Unaudited
1	Total Income from operations (Net)	-
2	Net Profit / (Loss) from ordinary activities' after tax	(421157.00)
3	Net Profit / (Loss) for the Period after tax (after Extraordinary items)	(421157.00)
4	Equity Share Capital	2490000.00
5	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)	-
6	Earnings per share	
	i) Basic (₹)	(1.69)
	ii) Diluted (₹)	(1.69)

NOTES:

The above is an extract of the detailed format of Financial Results filed with the stock exchange under the Regulation 33 of the SEBI Act, 2015. The full format of the Unaudited Financial Results are available on the Company's website www.templeleasing.co.in.